(Q46437707)

English

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

scientific article published in May 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

accelerated phase chronic myelogenous leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

1

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

5

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

Srdan Verstovsek

6

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

3

object named as

Susan O'Brien

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

9

object named as

Mary Beth Rios

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

4

object named as

Francis Giles

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

Guillermo Garcia-Manero

7

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

Jorge Eduardo Cortes

12

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

Richard E Champlin

10

object named as

Richard Champlin

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

8

object named as

Jianqin Shan

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

2

object named as

Moshe Talpaz

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

author name string

Marcos de Lima

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

103

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

2099-2108

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21032

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21032

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830345

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46437707&oldid=2111705799"